Ericaf Sim News Today

For children younger than 5 years, the incidence of respiratory syncytial virus (RSV) hospitalization increased in 2021 and 2022 compared with 2015 to 2019.

Researchers found that for all ages, the incidence rate ratios of hospitalization increased in 2021 and 2022 vs 2015 to 2019.

Children aged 24 to 59 months were 4.86 times as likely to be hospitalized in 2022 vs 2015 to 2019.

The respiratory syncytial virus (RSV) vaccine Abrysvo is approved for use in pregnant individuals to prevent the RSV in infants up to 6 months of age.

The FDA approved the first maternal vaccine to protect infants against RSV from birth to 6 months.

First and only U.S. approval of a maternal vaccine to help protect infants at birth through six months of life from lower respiratory tract disease and severe LRTD due to RSV FDA’s decision is...

Late-stage trials show Pfizer RSV vaccine candidate to be more than 80 percent effective at preventing severe illness in babies and seniors.

Pfizer announced that its respiratory syncytial virus (RSV) vaccine showed an efficacy of 82 percent against hospitalization in infants under 90 days old, and 69 percent among those younger than six months.

In a Phase III trial, Pfizer's RSVpreF, a bivalent RSV vaccine, protected infants against severe medically attended lower respiratory tract illness when administered during the second or third trimester.